BindingDB

The first public molecular recognition database, BindingDB supports research, education and practice in drug discovery, pharmacology and related fields.

BindingDB contains 3.2M data for 1.4M Compounds and 11.4K Targets. Of those, 1.6M data for 745K Compounds and 4.7K Targets were curated by BindingDB curators. BindingDB is a FAIRsharing resource.

If BindingDB was of value to your research, please take a moment to donate to this nonprofit project. Your donation will let us provide you with more data and improved service.

Donate Now

To help with training and testing AI and other models, BindingDB downloads and search results now provide the publication date and BindingDB curation date of each measurement.

Advanced Search

21 articles for F Narjes

The following articles (labelled with PubMed ID or TBD) are for your review

PMID
Data
Article Title
Organization
Identification of indole inhibitors of human hematopoietic prostaglandin D2 synthase (hH-PGDS).EBI
Astrazeneca
HTS followed by NMR based counterscreening. Discovery and optimization of pyrimidones as reversible and competitive inhibitors of xanthine oxidase.EBI
Astrazeneca
Discovery of (7R)-14-cyclohexyl-7-{[2-(dimethylamino)ethyl](methyl) amino}-7,8-dihydro-6H-indolo[1,2-e][1,5]benzoxazocine-11-carboxylic acid (MK-3281), a potent and orally bioavailable finger-loop inhibitor of the hepatitis C virus NS5B polymerase.EBI
P. Angeletti S.P.A. (Merck Research Laboratories)
SAR and pharmacokinetic studies on phenethylamide inhibitors of the hepatitis C virus NS3/NS4A serine protease.EBI
Merck Research Laboratories
Mechanism of hepatitis C virus RNA polymerase inhibition with dihydroxypyrimidines.EBI
Mcgill University
Discovery and Characterization of a Bicyclic Peptide (Bicycle) Binder to Thymic Stromal Lymphopoietin.EBI
BicycleTx Limited
Identification of thieno[3,2-b]pyrroles as allosteric inhibitors of hepatitis C virus NS5B polymerase.EBI
Mrl Rome
2-(2-Thienyl)-5,6-dihydroxy-4-carboxypyrimidines as inhibitors of the hepatitis C virus NS5B polymerase: discovery, SAR, modeling, and mutagenesis.EBI
P. Angeletti S.P.A. (Merck Research Laboratories)
Potent inhibitors of subgenomic hepatitis C virus RNA replication through optimization of indole-N-acetamide allosteric inhibitors of the viral NS5B polymerase.EBI
Irbm (Merck Research Laboratories Rome)
Development and preliminary optimization of indole-N-acetamide inhibitors of hepatitis C virus NS5B polymerase.EBI
Irbm (Merck Research Laboratories Rome)
Active site inhibitors of HCV NS5B polymerase. The development and pharmacophore of 2-thienyl-5,6-dihydroxypyrimidine-4-carboxylic acid.EBI
Mrl Rome
Capped dipeptide phenethylamide inhibitors of the HCV NS3 protease.EBI
Irbm, Mrl Rome
AZD0284, a Potent, Selective, and Orally Bioavailable Inverse Agonist of Retinoic Acid Receptor-Related Orphan Receptor C2.EBI
Astrazeneca
Phenethyl amides as novel noncovalent inhibitors of hepatitis C virus NS3/4A protease: discovery, initial SAR, and molecular modeling.EBI
Mrl Rome
Evolution, synthesis and SAR of tripeptide alpha-ketoacid inhibitors of the hepatitis C virus NS3/NS4A serine protease.EBI
Irbm, Mrl Rome
A designed P1 cysteine mimetic for covalent and non-covalent inhibitors of HCV NS3 protease.EBI
Irbm, Mrl Rome
Discovery of Potent and Orally Bioavailable Inverse Agonists of the Retinoic Acid Receptor-Related Orphan Receptor C2.EBI
Astrazeneca
Potent and Orally Bioavailable Inverse Agonists of RORĪ³t Resulting from Structure-Based Design.EBI
Astrazeneca
Thioether triazolopyridine and triazolopyrimidine inhibitors of myeloperoxidaseBDB
Bristol-Myers Squibb
1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazoles: identification of a potent aurora kinase inhibitor with a favorable antitumor kinase inhibition profile.BDB
Nerviano Medical Sciences